This week, MIT Technology Review published a feature on the future of IVF, and within 48 hours, the headlines fanned out across every health vertical: “AI fertility robots could make IVF more accessible.” “Automated IVF system targets US clinical launch in 2026.” “Nineteen babies and counting.”
If you’ve spent any time on fertility forums in the past few days, you’ve seen the screenshots. You’ve also probably seen the questions: Is robot IVF a real thing now? Should I wait for it? Will it be cheaper? Better? Will my clinic have it?
The short answer is that it’s coming, parts of it are already here, and almost none of it works the way the headlines suggest.
Below, we walk through what the AI and automation news actually describes, what’s available to patients in 2026 versus what’s still in trials, and what to ask your reproductive endocrinologist if you’re starting treatment in the next year.
What “Robot IVF” Actually Refers To
The phrase is doing a lot of work. When commentators say “robot IVF,” they’re usually pointing to one of three different things, and it’s worth pulling them apart.
The first is the platform that drove most of this week’s coverage: an automated IVF system called AURA, developed by Conceivable Life Sciences. According to MIT Technology Review’s reporting, the system handles parts of the embryology workflow that have historically depended on a skilled human embryologist looking through a microscope and moving cells with a tiny pipette. In a pilot study, AURA produced a 51% pregnancy rate and led to 19 healthy babies. Fox News’ coverage of the same research notes that the robot is roughly ten times more precise than humans at preparing the embryo culture plates that hold developing embryos during the first days of life.
The second is AI-driven embryo and sperm selection. This is already in clinical use at many clinics. AI tools analyze time-lapse images of developing embryos and rank them by their likelihood of leading to a live birth, and similar tools help embryologists pick the most viable sperm for procedures like ICSI. ASRM has been tracking these tools for years; the question now is how much they actually improve outcomes versus how much they standardize a process that already varies clinic to clinic.
The third is the more speculative frontier: gene editing of embryos to prevent inherited disease. This is not happening in clinical practice in the United States. It’s a research conversation, and a contentious one.
When someone says “robot IVF is here,” they almost always mean the second category — the AI selection tools — and sometimes the first. The third is years away, at minimum.
What’s Actually New This Year
Here’s what’s genuinely different about 2026 versus 2024 or 2025.
AURA is targeting a US clinical launch this year, pending validation. That’s the headline. According to Drug Target Review’s coverage of reproductive biotech, automation in IVF labs is moving from “interesting research” to “early commercial deployment” faster than most clinicians expected.
AI embryo selection tools are now embedded in major clinics’ workflows, not just being tested. If you walk into a Kindbody, Shady Grove, RMA, or CCRM clinic in 2026, there’s a reasonable chance an AI tool is helping rank your embryos.
In vitro maturation, the technique of maturing eggs in a lab dish rather than via heavy hormone stimulation in the body, is also having a moment. Drug Target Review describes a program from Gameto called Fertilo that uses lab-grown ovarian support cells to recreate the chemical environment of a young, healthy ovary. That program isn’t standard of care yet, but it’s moved from theory to clinical trials.
Underneath all of this is a quieter shift that matters more for most patients: the lab side of IVF, which has historically been the part most prone to human variability, is becoming more standardized. As one expert put the goal in MIT’s reporting: “Automation [will allow for] every patient to be treated in the same way in every single lab in the world.”
What the Success-Rate Numbers Actually Mean
This is where most readers get tripped up, because the numbers in the headlines sound bigger than they are.
A 51% pregnancy rate from a pilot study is a strong result. It is not a guarantee. Pilot studies are typically run on carefully selected patients in tightly controlled conditions, which means the result tells you what’s possible under good circumstances, not what the average outcome will be when the technology rolls out.
For context: per-cycle live birth rates from conventional IVF in 2025 ranged from roughly 50% in patients under 35 to under 10% by age 42, according to ASRM and CDC data. AI and automation tools, where they’re currently in clinical use, appear to nudge those numbers up by a few percentage points. They don’t replace the underlying biology of egg quality, sperm quality, and uterine environment.
Translation: the part the technology improves — embryologist precision, embryo selection — is real, and it matters. The part that limits IVF success in most patients (egg quality, especially after 35) is not what these tools fix. Recent Washington Post reporting on why female fertility declines with age makes the same point from the opposite direction: the bottleneck is biological, not procedural.
Where Experts Disagree
When you read the AURA coverage carefully, the optimism breaks along predictable lines.
The technologists and many of the lab leaders are bullish. They argue that automation will reduce variability, drive down costs by reducing the number of embryologists each cycle requires, and make IVF accessible in regions where there aren’t enough trained embryologists to meet demand. ACOG’s April 2026 update on IVF echoes that framing: the technology is “expanding possibilities for pregnancy.”
Many practicing reproductive endocrinologists are more cautious. The Cleveland Clinic and several university-affiliated REs interviewed by mainstream outlets have noted that the bottleneck for most patients is not lab precision; it’s egg quality, ovarian response, embryo aneuploidy, and uterine receptivity, all of which are biological problems automation doesn’t directly solve.
ASRM’s position is somewhere in the middle. They’ve signaled support for the careful adoption of AI tools and welcomed the standardization potential of automation, while emphasizing that all of these systems need rigorous, long-term outcome data before being marketed to patients as a meaningful upgrade.
The honest read: this is a real shift, and it’s likely to make the lab side of IVF more reliable. Whether it raises live birth rates meaningfully for the average patient is still an open question.
What This Means for Cost and Access
The case for cheaper IVF goes like this: a single IVF cycle in the US averages roughly $15,000 to $25,000 not counting medications, and a meaningful share of that cost is the time and skill of trained embryologists. If automation reduces that labor cost, the price could come down, especially in markets without strong pricing competition.
The counter-case is that new technology in healthcare almost never reduces cost in the short term. It usually adds a premium, especially while it’s branded as innovative. AURA and similar systems will likely be marketed as a higher-end option at first, not the default.
There’s a separate access conversation happening on the policy side. California’s SB 729, which took effect January 1, requires most large-group plans (101+ employees) to cover IVF including up to three egg retrievals. According to MultiState’s 2026 legislative tracker, more than half of US states introduced or carried over fertility coverage legislation this year. Federal guidance from the Departments of Labor, Treasury, and HHS now lets employers offer fertility benefits separately from major medical plans, similar to dental and vision. The Kindbody analysis of SB 729 notes that the law also redefines “infertility” in ways that broaden access for LGBTQ+ couples and single parents by choice.
The combination of slow but real coverage expansion and lab-side technology improvements is the actual story of 2026, not robots replacing doctors.
What’s Actually Coming Next
Three things to watch over the next 12 to 24 months, based on the current research pipeline.
Regulatory clearance for automated IVF systems. AURA is the most visible of several systems in trials. FDA pathways for medical devices in IVF labs are well-established but slow, and large-scale outcome data takes years to accumulate.
AI integration into PGT (preimplantation genetic testing). PGT-A, the test that screens embryos for chromosomal abnormalities, has gone from a minority of cycles in 2019 to the majority by 2024, according to MIT’s reporting. AI is now starting to interpret PGT results faster and possibly with more nuance, though the field is still divided on whether PGT-A actually improves outcomes for all patients or only specific subgroups.
In vitro gametogenesis (IVG). This is the much more speculative work of generating eggs and sperm from skin cells. It’s not in human trials. It’s not going to be available this year or next. But it’s the technology that, if it works, would change the entire shape of fertility medicine. Expect more headlines, fewer actual clinical milestones.
Practical Takeaways
If you’re starting IVF in the next 12 to 18 months, here are the questions worth asking your reproductive endocrinologist before you commit to a clinic.
1. Is your lab using AI for embryo selection? If yes, which platform, and what does the published validation data look like? A clinic should be able to answer this without defensiveness. If they can’t, that’s worth noting.
2. What’s your live birth rate per egg retrieval for someone in my age group, with similar diagnostic factors? Per-cycle rates are useful, but cumulative live birth rates per retrieval (including all embryo transfers from that retrieval) are more honest.
3. Are you using time-lapse imaging? If yes, what does it actually change about my treatment? Time-lapse incubators are the foundation many AI selection tools sit on top of. They’re not a magic bullet, but the data they produce is informative.
4. Do you participate in any clinical trials for automated IVF systems? If yes, ask what the trial structure is and what your options would be. If no, that’s not a strike against the clinic, but it tells you where they sit in the early-adopter landscape.
5. What’s the cost difference, if any, between conventional and AI-assisted protocols? Some clinics include AI selection at no extra cost. Others charge a premium. Knowing in advance helps you compare quotes meaningfully.
6. What’s your stance on PGT-A for someone with my profile? This is the technology question with the most actively debated patient impact. A good RE will explain when they recommend it and when they don’t.
The Bottom Line
The honest summary of this week’s news is that something is changing, but slowly, and the most important changes for patients are not the ones generating the biggest headlines. The lab side of IVF is becoming more precise. AI is helping embryologists do parts of their job more consistently. Coverage is expanding in some states. Costs may eventually come down.
What hasn’t changed, and won’t this year, is the underlying biology of conception, the time pressure of age, or the emotional weight of going through treatment. The tools are getting better. The waiting is still hard.
The conversation about robot IVF is going to keep growing. So will yours — with your doctor, with the people you love, with yourself. Take what’s useful from the headlines. Leave the rest.
Resources
MIT Technology Review: “What’s Next for IVF” — the May 2026 longform feature that drove this week’s coverage.
ACOG: “IVF: Expanding Possibilities for Pregnancy” (April 2026) — ACOG’s most recent patient-facing update on the state of IVF.
ASRM — the American Society for Reproductive Medicine’s patient resources, including its evolving guidance on AI in fertility.
Drug Target Review: “Fertility Beyond IVF” — a deeper look at the reproductive biotech pipeline, including IVM and Gameto’s Fertilo program.
RESOLVE: Insurance Coverage by State — the most up-to-date state-by-state map of fertility coverage mandates.
